Comparative Pharmacology
Head-to-head clinical analysis: ZARONTIN versus ZONISADE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZARONTIN versus ZONISADE.
ZARONTIN vs ZONISADE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethosuximide (Zarontin) suppresses paroxysmal 3 Hz spike-and-wave activity associated with absence seizures. The mechanism may involve inhibition of T-type calcium channels in thalamic neurons, reducing oscillatory burst firing.
Zonisamide is a sulfonamide anticonvulsant. Its precise mechanism of action is unknown, but it is believed to inhibit voltage-sensitive sodium channels and reduce T-type calcium currents, thereby stabilizing neuronal membranes and suppressing neuronal hypersynchronization. It may also modulate GABA and glutamate neurotransmission.
500 mg orally twice daily initially; may increase by 250 mg every 4-7 days. Maintenance: 1000-1500 mg/day in 2 divided doses; maximum 1500 mg/day.
100-200 mg orally every 8 hours; maximum 600 mg/day.
None Documented
None Documented
60 hours (range 40-70) in adults; 30-40 hours in children (due to higher clearance); clinical context: steady-state reached in ~10-14 days; may be reduced with enzyme-inducing co-medications.
Terminal elimination half-life: 63-69 hours in adults; allows once-daily dosing; steady-state achieved in 14-21 days
Renal: ~40% as unchanged drug; hepatic metabolism accounts for ~60% (primarily via CYP3A4, forming inactive metabolites); <1% fecal.
Renal: approximately 62% (35% unchanged, 27% as glucuronide conjugate); fecal: 3%; biliary: negligible
Category C
Category C
Anticonvulsant
Anticonvulsant